This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev
by Zacks Equity Research
Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.
Insulet (PODD) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Insulet (PODD) reports better-than-expected revenues for second-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.
Insulet (PODD) Q2 Earnings Lag Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -16.67% and 2.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Insulet (PODD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.
Insulet (PODD) Q1 Earnings Fall Shy of Estimates, Revenues Beat
by Zacks Equity Research
Insulet's (PODD) Q1 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.
Insulet (PODD) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -100.00% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Up 0.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insulet's (PODD) Omnipod 5 Pivotal Trial Outcome Favorable
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 pivotal study showed improvement in glucose control, verified by notable reduction in HbA1c and enhanced time in range together with the lowest rates of hypoglycemia.
4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.
Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat
by Zacks Equity Research
Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.
Insulet (PODD) Omnipod DASH Reaches Canada, Global Hold Widens
by Zacks Equity Research
Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.
Insulet (PODD) Down 0.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume
Insulet (PODD) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 183.33% and 5.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Insulet (PODD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) third-quarter results benefit from solid segmental performance.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Varian's (VAR) receipt of 10 Ethos orders in Q4 instills optimism
LabCorp (LH) Q3 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
LabCorp (LH) Diagnostics business in Q3 grows significantly on organic volume improvements as a result of growing demand for COVID-19 testing.
Ecolab (ECL) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Although Ecolab's (ECL) third-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
NextGen Healthcare (NXGN) Gains 8.1% Post Q2 Earnings Beat
by Zacks Equity Research
NextGen (NXGN) benefited from both its operating segments in Q2.
Quest Diagnostics' (DGX) Q3 Earnings Beat, Base Volume Rises
by Zacks Equity Research
In Q3, Quest Diagnostics (DGX) sees strong signs of the health care system returning to pre-pandemic levels
Align Technology (ALGN) Beats on Q3 Earnings, Margins Up
by Zacks Equity Research
Align Technology's (ALGN) segments report solid rebound in sales across geographies despite the pandemic-led business challenges.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Margins Up
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q3.